(Q37195685)

18 August 2017

1 reference

title

Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders (English)

1 reference

18 August 2017

Nicholas C P Cross

1

1 reference

PubMed ID

18566537

18 August 2017

Andreas Reiter

series ordinal

2

1 reference

18 August 2017

20 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

119

1 reference

18 August 2017

4

1 reference

18 August 2017

199-206

1 reference

Eosinophilia: secondary, clonal and idiopathic

18 August 2017

1 reference

Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy

21 January 2018

1 reference

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders

21 January 2018

1 reference

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

21 January 2018

1 reference

Oncogenic kinase signalling

21 January 2018

1 reference

FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice

21 January 2018

1 reference

Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations

21 January 2018

1 reference

Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.

21 January 2018

1 reference

14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells

21 January 2018

1 reference

Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.

21 January 2018

1 reference

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

21 January 2018

1 reference

Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?

21 January 2018

1 reference

KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.

21 January 2018

1 reference

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

21 January 2018

1 reference

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

21 January 2018

1 reference

Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent

21 January 2018

1 reference

TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle

21 January 2018

1 reference

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

21 January 2018

1 reference

The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease

21 January 2018

1 reference

Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581

21 January 2018

1 reference

Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

21 January 2018

1 reference

Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome.

21 January 2018

1 reference

Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

21 January 2018

1 reference

The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

21 January 2018

1 reference

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

21 January 2018

1 reference

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders

21 January 2018

1 reference

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

21 January 2018

1 reference

FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000140631

1 reference

18 August 2017

1 reference

PubMed ID

18566537